Literature DB >> 27709471

Natural history of graves' orbitopathy after treatment.

Francesca Menconi1, Marenza Leo1, Elena Sabini1, Teresa Mautone2, Marco Nardi2, Aldo Sainato3, Stefano Sellari-Franceschini4, Paolo Vitti1, Claudio Marcocci1, Michele Marinò5.   

Abstract

Intravenous glucocorticoids are used for Graves' orbitopathy, alone or associated with/followed by additional treatments (orbital radiotherapy, orbital decompression, palpebral or eye surgery). However, the relation between associated/additional treatments and other variables with Graves' orbitopathy outcome following intravenous glucocorticoids is not clear. Thus, the present study was conducted to investigate retrospectively the impact of associated/additional treatments and other variables on Graves' orbitopathy outcome after intravenous glucocorticoids. We evaluated 226 untreated Graves' orbitopathy patients. Following first observation, patients were given intravenous glucocorticoids and re-examined after a median of 46.5 months. The end-points were the relation between Graves' orbitopathy outcome, outcome of NOSPECS score and of the single Graves' orbitopathy features with several variables, including associated/additional treatments. All Graves' orbitopathy features improved significantly after treatment. Overall, Graves' orbitopathy improved in ~60 % of patients (responders), whereas it was stable or worsened in ~40 % of patients (non-responders). Time between first and last observation and clinical activity score at first observation correlated significantly with Graves' orbitopathy outcome. The outcomes of NOSPECS, eyelid aperture, clinical activity score and diplopia correlated with time between the first and last observation. The NOSPECS outcome correlated with gender. The outcomes of proptosis, eyelid aperture and visual acuity correlated with orbital decompression. The outcome of diplopia correlated with orbital radiotherapy. Taking into account the limitations of retrospective investigations, our findings confirm that time (i.e. the natural history of Graves' orbitopathy) is a key factor in determining the long-term outcome of Graves' orbitopathy, radiotherapy is effective for diplopia, and orbital decompression is followed by an amelioration of several Graves' orbitopathy features.

Entities:  

Keywords:  Age; Glucocorticoids; Graves’ disease; Graves’ orbitopathy; Natural history; Radiotherapy

Mesh:

Substances:

Year:  2016        PMID: 27709471     DOI: 10.1007/s12020-016-1136-x

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  24 in total

1.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

Review 2.  Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers.

Authors:  W M Wiersinga; P Perros; G J Kahaly; M P Mourits; L Baldeschi; K Boboridis; A Boschi; A J Dickinson; P Kendall-Taylor; G E Krassas; C M Lane; J H Lazarus; C Marcocci; M Marino; M Nardi; C Neoh; J Orgiazzi; A Pinchera; S Pitz; M F Prummel; M S Sartini; M Stahl; G von Arx
Journal:  Eur J Endocrinol       Date:  2006-09       Impact factor: 6.664

Review 3.  Total thyroid ablation in Graves' orbitopathy.

Authors:  F Menconi; M Leo; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

Review 4.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

5.  Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial.

Authors:  Mariacarla Moleti; Maria Antonia Violi; Daniela Montanini; Costantino Trombetta; Beatrice Di Bella; Giacomo Sturniolo; Silvia Presti; Angela Alibrandi; Alfredo Campennì; Sergio Baldari; Francesco Trimarchi; Francesco Vermiglio
Journal:  J Clin Endocrinol Metab       Date:  2014-01-16       Impact factor: 5.958

6.  Rehabilitative orbital decompression for Graves' orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients' satisfaction.

Authors:  Roberto Rocchi; Riccardo Lenzi; Michele Marinò; Francesco Latrofa; Marco Nardi; Paolo Piaggi; Barbara Mazzi; Maria Antonietta Altea; Aldo Pinchera; Paolo Vitti; Claudio Marcocci; Stefano Sellari-Franceschini
Journal:  Thyroid       Date:  2012-10-16       Impact factor: 6.568

7.  A treatment strategy for Graves' orbitopathy.

Authors:  Claudio Marcocci; Aldo Pinchera; Michele Marinò
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-05

8.  Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.

Authors:  C Marcocci; L Bartalena; F Bogazzi; G Bruno-Bossio; A Lepri; A Pinchera
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

9.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

10.  Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone.

Authors:  L Bartalena; C Marcocci; L Chiovato; M Laddaga; G Lepri; D Andreani; G Cavallacci; L Baschieri; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

View more
  2 in total

1.  Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.

Authors:  S Seo; M Sánchez Robledo
Journal:  J Endocrinol Invest       Date:  2018-09-07       Impact factor: 4.256

Review 2.  Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Eliana Piantanida; Daniela Gallo; Adriana Lai; Maria Laura Tanda
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-30       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.